Current insights in obstetric antiphospholipid syndrome

Area of Science:

• Obstetrics and Gynecology
• Rheumatology
• Hematology

Background:

• Antiphospholipid syndrome (APS) is characterized by blood clots and/or pregnancy complications in patients with antiphospholipid antibodies (aPL).
• Obstetric morbidity is a significant concern in APS, encompassing conditions like fetal growth restriction, preeclampsia, and intrauterine death.
• APS is a leading acquired risk factor for recurrent pregnancy loss and placental dysfunction.

Purpose of the Study:

• To review the clinical manifestations of APS, with a specific emphasis on obstetric complications.
• To discuss current management strategies for obstetric APS.
• To explore future therapeutic directions for APS.

Main Methods:

• This is a review article, synthesizing existing literature on antiphospholipid syndrome and obstetric complications.
• Key clinical presentations, management protocols, and emerging treatments are discussed.
• Evidence from retrospective studies on alternative therapies is considered.

Main Results:

• Aspirin and heparin therapy lead to successful pregnancy outcomes in approximately 70% of women with obstetric APS.
• Current standard treatments are insufficient, failing in 20-30% of APS pregnancies.
• Emerging treatments like pravastatin and hydroxychloroquine show promise in managing aPL-related pregnancy complications.

Conclusions:

• Antiphospholipid syndrome poses significant risks for pregnancy, including recurrent pregnancy loss and placental dysfunction.
• While aspirin and heparin are mainstays of treatment, they do not prevent all complications.
• Further research into alternative and novel treatment options is urgently required to improve obstetric outcomes in APS.